IP Library Granted Patent US 10,668,041
Granted Patent B2
US 10,668,041 · App. 15/690,520 · Granted Jun 2, 2020

Compositions and methods comprising medium chain triglycerides for treatment of epilepsy

Inventors: Yuanlong Pan (Chesterfield, MO); Brian Michael Zanghi (Ballwin, MO); Jean-Christophe Bouthegourd (Sannois, FR)
Assignee: Societe des Produits Nestle SA
A61K31/23A23K20/147A23K20/158A23K20/20A23K50/40A23K50/42A23K50/45A23K50/48A23L33/115A23L33/12A23L33/125A23L33/21A23L33/40A61K9/0056A61K31/198A61K31/4015A61K31/515A61K31/5377A61K31/5513A61K33/00A61K45/06A23V2002/00A23V2200/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,668,041
App. No.
15/690,520
Granted
Jun 2, 2020
Kind
B2
Abstract

The invention provides compositions and methods for treatment of epilepsy in an animal. In one embodiment, a method for treating epilepsy in a companion animal can comprise administering to the companion animal a food composition comprising a medium chain triglyceride (MCT), wherein the MCT is present in the food composition in an effective amount for reducing or preventing seizures when the food composition is administered to the companion animal.

Claims (14)

1. A method for treating epilepsy in a companion animal comprising administering to the companion animal a food composition comprising a medium chain triglyceride (MCT) about 15% to about 50% protein, wherein the MCT is present in the food composition from about 1% to about 7% by weight and is effective for reducing seizures when the food composition is administered to the companion animal, wherein the MCT is of a formula (Formula 1):

wherein the R′, R″, and R″′ esterified to the glycerol backbone are each independent fatty acids having 5-12 carbons.

2. The method of claim 1 , wherein the animal is a canine.

3. The method of claim 1 , wherein the animal is a feline.

4. The method of claim 1 , wherein the food composition comprises a nitric oxide releasing compound (NORC).

5. The method of claim 4 , wherein the NORC is arginine.

6. The method of claim 1 , wherein greater than about 95% of the R′, R″, and R″′ are 8 carbons in length.

7. The method of claim 1 , wherein the remaining R′, R″, and R″′ are 6-carbon or 10-carbon fatty acids.

8. The method of claim 1 , further comprising administering an anti-epileptic drug (AED) to the companion animal, wherein the AED is selected from the group consisting of acetazolamide, carbamazepine, chlorazepate, clobazam, clonazepam, diazepam, eslicarbazepine acetate, ethisyxunudem, ethosuximide, felbamate, gabapentin, imepitoin, keppra, lacosamide, lamotrigine, levetiracetam, methylphenobarbitone, nitrazepam, oxcarbazepine, perampanel, piracetam, phenobarbital, phenytoin, potassium bromide, pregabalin, primidone, retigabine, rufinamide, sodium bromide, sodium valproate, stiripentol, sulthiame, tiagabine, topiramate, valporic acid, vigabatrin, zonisamide, salts thereof, derivatives thereof, and mixtures thereof.

9. The method of claim 1 , wherein the food composition is formulated as a pet food composition or a dietary supplement.

10. The method of claim 1 , wherein the food composition further comprises, about 5% to about 40% fat, about 5% to about 10% ash content, and having a moisture content of about 5% to about 20%.

11. The method of claim 1 , wherein the food composition includes an AED, wherein the AED is selected from the group consisting of acetazolamide, carbamazepine, chlorazepate, clobazam, clonazepam, diazepam, eslicarbazepine acetate, ethisyxunudem, ethosuximide, felbamate, gabapentin, imepitoin, keppra, lacosamide, lamotrigine, levetiracetam, methylphenobarbitone, nitrazepam, oxcarbazepine, perampanel, piracetam, phenobarbital, phenytoin, potassium bromide, pregabalin, primidone, retigabine, rufinamide, sodium bromide, sodium valproate, stiripentol, sulthiame, tiagabine, topiramate, valporic acid, vigabatrin, zonisamide, salts thereof, derivatives thereof, and mixtures thereof.

12. The method of claim 1 , wherein the food composition is administered on a regular basis.

13. The method of claim 1 , wherein the food composition is administered on a regular basis for a period of at least one month.

Assignments (7)
RELEASE OF SECURITY INTEREST IN CERTAIN INTELLECTUAL PROPERTY Recorded Jul 8, 2022
From: OXFORD FINANCE LLC
To: KALA PHARMACEUTICALS, INC.
Reel/Frame 060614/0713 →
SECURITY INTEREST Recorded May 6, 2021
From: KALA PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC
Reel/Frame 056168/0602 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2017
From: PAN, YUANLONG; ZANGHI, BRIAN MICHAEL; BOUTHEGOURD, JEAN-CHRISTOPHE
To: NESTEC SA
Reel/Frame 043446/0396 →
Continuity (3)
Continuation In Part 14960559 · Dec 7, 2015
Provisional Application 62088797 · Dec 8, 2014
Related Publication 20170360739A1 · Dec 21, 2017